Glioblastoma: State of the Art and Future Perspectives

Message from the Guest Editors

Glioblastoma is one of the most common types of primary cancer in the central nervous system. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, resistance to therapy, migration and invasion, immunosuppression. With the entry of novel high-throughput technologies, significant progress has been made to understand molecular and immunological signatures underlying the pathology of glioblastoma. Here, we aim at updating researchers and clinicians to provide a systemic view on glioblastoma by highlighting the progress made in basic, preclinical and clinical research and outlining future challenges. To this end, we welcome articles on basic, preclinical and clinical research in glioblastoma. In addition, we will present invited review articles on the topics of neurosurgical approaches, neuropathology and genetics, preclinical research and mouse models of glioblastoma, imaging, radiation therapy and tumor-treating fields, alkylating chemotherapy, immunotherapy, investigational therapies and precision oncology trials in glioblastoma.
Message from the Editor-in-Chief

Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews. Citations available in PubMed, full-text archived in PubMed Central. Indexed in BIOSIS Previews, Scopus and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 16.9 days after submission; acceptance to publication is undertaken in 4.2 days (median values for papers published in this journal in the second half of 2018).

Contact Us

Cancers  Tel: +41 61 683 77 34  mdpi.com/journal/cancers
MDPI, St. Alban-Anlage 66  Fax: +41 61 302 89 18   cancers@mdpi.com
4052 Basel, Switzerland  www.mdpi.com  @Cancers_MDPI